Axonics® to Participate in the Piper Sandler Healthcare Conference

Rhea-AI Summary

Axonics, Inc. (Nasdaq: AXNX), a medical technology company, will participate in the Piper Sandler Healthcare Conference on December 1, 2022, presenting at 11:00 a.m. Eastern Time. Investors can access a live webcast and replay on the Axonics investor relations website. The company specializes in treatments for bladder and bowel dysfunction, ranking No. 1 on the Financial Times' list of the 500 fastest-growing companies in the Americas in 2022, and No. 4 on Deloitte's Technology Fast 500. Axonics offers sacral neuromodulation systems and Bulkamid® for symptom relief.

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will participate in the Piper Sandler Healthcare Conference on December 1, 2022.

Axonics is scheduled to present at 11:00 a.m. Eastern Time. A live webcast and archived replay of the presentation will be accessible on the Axonics investor relations website.

About Axonics

Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 1 on the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas and No. 4 on the 2022 Deloitte Technology Fast 500™ following its No. 1 ranking in 2021.

Axonics sacral neuromodulation (SNM) systems provide patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company’s best-in-class urethral bulking hydrogel, Bulkamid^®, provides safe and durable symptom relief to women with stress urinary incontinence (SUI). Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. SUI affects an estimated 29 million women in the U.S. alone. Axonics’ clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. For more information, visit www.axonics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221118005032/en/

Axonics

Neil Bhalodkar

Investor Relations

949-336-5293

ir@axonics.com

Source: Axonics, Inc.

FAQ

When is Axonics presenting at the Piper Sandler Healthcare Conference?

Axonics will present on December 1, 2022, at 11:00 a.m. Eastern Time.

What products does Axonics develop for bladder and bowel dysfunction?

Axonics develops sacral neuromodulation systems and Bulkamid® for treating bladder and bowel dysfunction.

How did Axonics rank in the Financial Times' fastest-growing companies list?

Axonics ranked No. 1 on the Financial Times' 2022 list of the 500 fastest growing companies in the Americas.

Where can I watch Axonics' conference presentation?

A live webcast and archived replay of Axonics' presentation can be accessed on their investor relations website.